Receptor and enzyme expression for prostanoid metabolism in colorectal cancer related to tumor tissue PGE2

International Journal of Oncology

Volumn 36, Issue 2, 2010, Pages 469-478

  Gustafsson, Annika ^a   Andersson, Marianne ^a   Lagerstedt, Kristina ^a   Lönnroth, Christina ^a   Nordgren, Svante ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colon cancer; COX 2; Non steroidal anti inflammatory drug; Prostaglandins

Indexed keywords

ACUTE PHASE PROTEIN; ESOMEPRAZOLE; INDOMETACIN; INTERLEUKIN 3; INTERLEUKIN 7; PROSTAGLANDIN E2; PROSTANOID; RNA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE INTESTINE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; DINOPROSTONE; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTAGLANDINS; RADIOIMMUNOASSAY; RECEPTORS, PROSTAGLANDIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 75649095204     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000521     Document Type: Article

References (45)

1. Gelin J, Andersson C and Lundholm K: Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 51: 880-885, 1991.
2. Cahlin C, Gelin J, Andersson M, Lönnroth C and Lundholm K: The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol 27: 913-923, 2005.
3. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, Lonnroth C and Lundholm K: EP(1-4) subtype, COX and PPARgamma receptor expression in colorectal cancer in prediction of disease-specific mortality. Int J Cancer 121: 232-240, 2007.
4. Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002.
5. Pradono P, Tazawa R, Maemondo M, Tanaka M, Usui K, Saijo Y, Hagiwara K and Nukiwa T: Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res 62: 63-66, 2002.
6. Wang D and Dubois RN: Prostaglandins and cancer. Gut 55: 115-122, 2006.
7. Hull MA, Ko SC and Hawcroft G: Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 3: 1031-1039, 2004.
8. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
9. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58: 362-366, 1998.
10. Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001.
11. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C and Lundholm K: Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol: 1107-1112, 2007.
12. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386, 2009.
13. Herschman HR: Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125-140, 1996.
14. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, De Lellis RA, Subbaramaiah K and Dannenberg AJ: Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7: 3971-3976, 2001.
15. Gupta RA and Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21, 2001.
16. Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR and Giardiello FM: Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 58: 1750-1753, 1998.
17. Rigas B, Goldman IS and Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122: 518-523, 1993.
18. Pinto S, Gori L, Gallo O, Boccuzzi S, Paniccia R and Abbate R: Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids 49: 527-530, 1993.
19. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K and Markowitz SD: 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-betainduced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 101: 17468-17473, 2004.
20. Lönnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K and Lundholm K: Preoperative treatment with a non-steroidal antiinflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer Cancer Immun 8: 5, 2008.
21. Pocock SJ and Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103-115, 1975.
22. Lönnroth C, Andersson M and Lundholm K: Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18: 929-937, 2001.
23. Axelsson H, Lönnroth C, Andersson M, Wang W and Lundholm K: Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. Cancer Inform 2: 199-213, 2007.
24. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, Korner U, Gulich M, Karrefors I, Norli B, Hafström L, Kewenter J, Olbe L and Lundell L: Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54: 5602-5606, 1994.
25. Cahlin C: Cyclooxygenase activity and tumor progression. Gothenburg: University of Gothenburg, Thesis, 2008.
26. Lundholm K, Daneryd P, Korner U, Hyltander A and Bosaeus I: Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 24: 505-512, 2004.
27. Wang W, Andersson M, Lönnroth C, Svanberg E and Lundholm K: Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Clin Cancer Res 24: 99-107, 2005.
28. Cahlin C, Lönnroth C, Arvidsson A, Nordgren S and Lundholm K: Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol 32: 909-918, 2008.
29. Huang RH, Chai J and Tarnawski AS: Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J Gastroenterol 12: 6446-6452, 2006.
30. Wise H: Multiple signalling options for prostacyclin. Acta Pharmacol Sin 24: 625-630, 2003.
31. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD and Coffey RJ: Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res 63: 1748-1751, 2003.
32. Hirai H, Tanaka K, Takano S, Ichimasa M, Nakamura M and Nagata K: Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J Immunol 168: 981-985, 2002.
33. + mice. Cancer Res 67: 881-889, 2007.
34. Gosset P, Bureau F, Angeli V, Pichavant M, Faveeuw C, Tonnel AB and Trottein F: Prostaglandin D2 affects the maturation of human monocyte-derived dendritic cells: consequence on the polarization of naive Th cells. J Immunol 170: 4943-4952, 2003.
35. Yoshimura-Uchiyama C, Iikura M, Yamaguchi M, Nagase H, Ishii A, Matsushima K, Yamamoto K, Shichijo M, Bacon KB and Hirai K: Differential modulation of human basophil functions through prostaglandin D2 receptors DP and chemoattractant receptor-homologous molecule expressed on Th2 cells/DP2. Clin Exp Allergy 34: 1283-1290, 2004.
36. Yoshida T, Ohki S, Kanazawa M, Mizunuma H, Kikuchi Y, Satoh H, Andoh Y, Tsuchiya A and Abe R: Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. Surg Today 28: 740-745, 1998.
37. Park BH, Breyer B and He TC: Peroxisome proliferator-activated receptors: roles in tumorigenesis and chemoprevention in human cancer. Curr Opin Oncol 13: 78-83, 2001.
38. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, Milne GL, Katkuri S and DuBois RN: 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280: 3217-3223, 2005.
39. Quidville V, Segond N, Pidoux E, Cohen R, Jullienne A and Lausson S: Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology 145: 2561-2571, 2004.
40. Frenkian M, Segond N, Pidoux E, Cohen R and Jullienne A: Indomethacin, a COX inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation. Prostaglandins Other Lipid Mediat 65: 11-20, 2001.
41. Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Nakahara K, Jenkins J, Cliatt J, Humbyrd CJ, Denobile J, Soballe P, Gallinger S, Buchbinder A, Gordon G, Hawk E and Kirsch IR: Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15: 1382-1391, 2006.
42. Auman JT, Church R, Lee SY, Watson MA, Fleshman JW and McLeod HL: Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 44: 1754-1760, 2008.
43. Bosserhoff AK: Melanoma inhibitory activity (MIA): an important molecule in melanoma development and progression. Pigment Cell Res 18: 411-416, 2005.
44. El Fitori J, Kleeff J, Giese NA, Guweidhi A, Bosserhoff AK, Buchler MW and Friess H: Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells. Cancer Cell Int 5: 3, 2005.
45. Lönnroth C, Svaninger G, Gelin J, Cahlin C, Iresjö B-M, Cvetkovska E, Edström S, Andersson M, Svanberg E and Lundholm K: Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int J Oncol 7: 1405-1413, 1995.